|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: PSMA8 |
Gene summary for PSMA8 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | PSMA8 | Gene ID | 143471 |
| Gene name | proteasome 20S subunit alpha 8 | |
| Gene Alias | PSMA7L | |
| Cytomap | 18q11.2 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | Q8TAA3 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 143471 | PSMA8 | HTA11_2487_2000001011 | Human | Colorectum | SER | 3.37e-03 | 1.64e-01 | -0.1808 |
| 143471 | PSMA8 | HTA11_1938_2000001011 | Human | Colorectum | AD | 8.45e-11 | 3.44e-01 | -0.0811 |
| 143471 | PSMA8 | HTA11_78_2000001011 | Human | Colorectum | AD | 7.41e-14 | 4.66e-01 | -0.1088 |
| 143471 | PSMA8 | HTA11_347_2000001011 | Human | Colorectum | AD | 2.61e-17 | 3.93e-01 | -0.1954 |
| 143471 | PSMA8 | HTA11_3361_2000001011 | Human | Colorectum | AD | 2.22e-02 | 2.39e-01 | -0.1207 |
| 143471 | PSMA8 | HTA11_83_2000001011 | Human | Colorectum | SER | 4.23e-03 | 1.42e-01 | -0.1526 |
| 143471 | PSMA8 | HTA11_696_2000001011 | Human | Colorectum | AD | 2.77e-07 | 2.21e-01 | -0.1464 |
| 143471 | PSMA8 | HTA11_1391_2000001011 | Human | Colorectum | AD | 2.44e-13 | 4.56e-01 | -0.059 |
| 143471 | PSMA8 | HTA11_7862_2000001011 | Human | Colorectum | AD | 1.24e-02 | 1.54e-01 | -0.0179 |
| 143471 | PSMA8 | HTA11_6801_2000001011 | Human | Colorectum | SER | 2.21e-02 | 2.31e-01 | 0.0171 |
| 143471 | PSMA8 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 4.63e-05 | 1.97e-01 | 0.294 |
| 143471 | PSMA8 | HTA11_99999965104_69814 | Human | Colorectum | MSS | 2.22e-02 | 1.15e-01 | 0.281 |
| 143471 | PSMA8 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 1.21e-06 | 2.62e-01 | 0.3859 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0010498 | Colorectum | AD | proteasomal protein catabolic process | 174/3918 | 490/18723 | 3.18e-14 | 7.66e-12 | 174 |
| GO:00104981 | Colorectum | SER | proteasomal protein catabolic process | 132/2897 | 490/18723 | 3.08e-11 | 5.55e-09 | 132 |
| GO:00104982 | Colorectum | MSS | proteasomal protein catabolic process | 157/3467 | 490/18723 | 2.39e-13 | 5.25e-11 | 157 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa05012 | Colorectum | AD | Parkinson disease | 147/2092 | 266/8465 | 2.53e-27 | 8.48e-25 | 5.41e-25 | 147 |
| hsa05010 | Colorectum | AD | Alzheimer disease | 174/2092 | 384/8465 | 1.82e-19 | 9.26e-18 | 5.91e-18 | 174 |
| hsa05016 | Colorectum | AD | Huntington disease | 147/2092 | 306/8465 | 1.93e-19 | 9.26e-18 | 5.91e-18 | 147 |
| hsa05020 | Colorectum | AD | Prion disease | 133/2092 | 273/8465 | 2.47e-18 | 8.29e-17 | 5.29e-17 | 133 |
| hsa05014 | Colorectum | AD | Amyotrophic lateral sclerosis | 164/2092 | 364/8465 | 4.28e-18 | 1.27e-16 | 8.09e-17 | 164 |
| hsa05022 | Colorectum | AD | Pathways of neurodegeneration - multiple diseases | 201/2092 | 476/8465 | 4.54e-18 | 1.27e-16 | 8.09e-17 | 201 |
| hsa03050 | Colorectum | AD | Proteasome | 29/2092 | 46/8465 | 3.87e-08 | 6.18e-07 | 3.94e-07 | 29 |
| hsa05017 | Colorectum | AD | Spinocerebellar ataxia | 60/2092 | 143/8465 | 3.78e-06 | 4.35e-05 | 2.78e-05 | 60 |
| hsa050121 | Colorectum | AD | Parkinson disease | 147/2092 | 266/8465 | 2.53e-27 | 8.48e-25 | 5.41e-25 | 147 |
| hsa050101 | Colorectum | AD | Alzheimer disease | 174/2092 | 384/8465 | 1.82e-19 | 9.26e-18 | 5.91e-18 | 174 |
| hsa050161 | Colorectum | AD | Huntington disease | 147/2092 | 306/8465 | 1.93e-19 | 9.26e-18 | 5.91e-18 | 147 |
| hsa050201 | Colorectum | AD | Prion disease | 133/2092 | 273/8465 | 2.47e-18 | 8.29e-17 | 5.29e-17 | 133 |
| hsa050141 | Colorectum | AD | Amyotrophic lateral sclerosis | 164/2092 | 364/8465 | 4.28e-18 | 1.27e-16 | 8.09e-17 | 164 |
| hsa050221 | Colorectum | AD | Pathways of neurodegeneration - multiple diseases | 201/2092 | 476/8465 | 4.54e-18 | 1.27e-16 | 8.09e-17 | 201 |
| hsa030501 | Colorectum | AD | Proteasome | 29/2092 | 46/8465 | 3.87e-08 | 6.18e-07 | 3.94e-07 | 29 |
| hsa050171 | Colorectum | AD | Spinocerebellar ataxia | 60/2092 | 143/8465 | 3.78e-06 | 4.35e-05 | 2.78e-05 | 60 |
| hsa050122 | Colorectum | SER | Parkinson disease | 132/1580 | 266/8465 | 2.72e-31 | 9.03e-29 | 6.55e-29 | 132 |
| hsa050202 | Colorectum | SER | Prion disease | 119/1580 | 273/8465 | 4.61e-22 | 3.06e-20 | 2.22e-20 | 119 |
| hsa050162 | Colorectum | SER | Huntington disease | 127/1580 | 306/8465 | 3.29e-21 | 1.37e-19 | 9.92e-20 | 127 |
| hsa050102 | Colorectum | SER | Alzheimer disease | 146/1580 | 384/8465 | 6.52e-20 | 2.40e-18 | 1.75e-18 | 146 |
| Page: 1 2 3 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| PSMA8 | SNV | Missense_Mutation | novel | c.274N>G | p.Ile92Val | p.I92V | Q8TAA3 | protein_coding | tolerated(0.61) | benign(0.03) | TCGA-A8-A07P-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | SD |
| PSMA8 | SNV | Missense_Mutation | novel | c.51C>A | p.His17Gln | p.H17Q | Q8TAA3 | protein_coding | deleterious(0.01) | benign(0.254) | TCGA-AC-A5EH-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| PSMA8 | SNV | Missense_Mutation | novel | c.164N>C | p.Leu55Pro | p.L55P | Q8TAA3 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| PSMA8 | SNV | Missense_Mutation | novel | c.325N>T | p.Pro109Ser | p.P109S | Q8TAA3 | protein_coding | deleterious(0.05) | benign(0.009) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| PSMA8 | SNV | Missense_Mutation | c.546N>C | p.Lys182Asn | p.K182N | Q8TAA3 | protein_coding | deleterious(0.02) | probably_damaging(0.954) | TCGA-BI-A0VS-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| PSMA8 | SNV | Missense_Mutation | rs777581252 | c.101N>T | p.Ala34Val | p.A34V | Q8TAA3 | protein_coding | tolerated(0.2) | benign(0.122) | TCGA-EA-A3HU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| PSMA8 | SNV | Missense_Mutation | c.20N>A | p.Arg7Lys | p.R7K | Q8TAA3 | protein_coding | deleterious(0.02) | probably_damaging(0.994) | TCGA-A6-6654-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | oxaliplatin | SD | |
| PSMA8 | SNV | Missense_Mutation | c.584N>A | p.Ala195Asp | p.A195D | Q8TAA3 | protein_coding | deleterious(0) | possibly_damaging(0.786) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| PSMA8 | SNV | Missense_Mutation | novel | c.747G>T | p.Lys249Asn | p.K249N | Q8TAA3 | protein_coding | tolerated(0.22) | benign(0.014) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| PSMA8 | SNV | Missense_Mutation | novel | c.607N>G | p.Leu203Val | p.L203V | Q8TAA3 | protein_coding | deleterious(0.01) | probably_damaging(0.917) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 143471 | PSMA8 | DRUGGABLE GENOME, PROTEASE | CARFILZOMIB | CARFILZOMIB | 24524217 | |
| 143471 | PSMA8 | DRUGGABLE GENOME, PROTEASE | inhibitor | CHEMBL3545432 | IXAZOMIB CITRATE | |
| 143471 | PSMA8 | DRUGGABLE GENOME, PROTEASE | inhibitor | BORTEZOMIB | BORTEZOMIB | |
| 143471 | PSMA8 | DRUGGABLE GENOME, PROTEASE | inhibitor | CHEMBL371405 | MARIZOMIB | |
| 143471 | PSMA8 | DRUGGABLE GENOME, PROTEASE | BORTEZOMIB | BORTEZOMIB | 24524217 | |
| 143471 | PSMA8 | DRUGGABLE GENOME, PROTEASE | inhibitor | CHEMBL2103884 | OPROZOMIB | |
| 143471 | PSMA8 | DRUGGABLE GENOME, PROTEASE | inhibitor | CARFILZOMIB | CARFILZOMIB | |
| 143471 | PSMA8 | DRUGGABLE GENOME, PROTEASE | inhibitor | CHEMBL451887 | CARFILZOMIB | |
| 143471 | PSMA8 | DRUGGABLE GENOME, PROTEASE | inhibitor | CHEMBL325041 | BORTEZOMIB |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |